Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Invivyd Logo
Invivyd Growth Score
92
CB Rank
1851
Heat Score
57
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Founded
obfuscation
PublicPost-IPO Equity Waltham, Massachusetts, United States101-250 invivyd.com/
Biotechnology
Pharmaceutical
Therapeutics
Overview

Invivyd
Total Funding
obfuscation
Growth Score
92
Heat Score
57

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score92
-6 pts
in past quarter
Heat Score 57
-7 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Invivyd

CB Rank
1851
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Founded
obfuscation
PublicPost-IPO Equity Waltham, Massachusetts, United States101-250 invivyd.com/
Biotechnology
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name Invivyd, Inc.
Also Known As Adagio Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:IVVD
Company Type For Profit
Founders  Laura Walker, Tillman Gerngross
About the Company
Invivyd is a commercial-stage biopharmaceutical company that delivers protection from serious viral infectious diseases. It is on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2.
Phone Number +1 781-819-0080
Contact Email info@invivyd.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Invivyd is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

PEMGARDA® (pemivibart)
A monoclonal antibody authorized for emergency use as pre-exposure prophylaxis to prevent COVID-19 in certain immunocompromised adults and adolescents.
VYD2311
An investigational monoclonal antibody candidate in early clinical development for prevention or treatment of COVID-19.

Research & Development

Invivyd is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Invivyd Logo
Post-IPO Equity - Invivyd
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - Invivyd Logo
Post-IPO Debt - Invivyd
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - Invivyd Logo
Post-IPO Debt - Invivyd
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - Invivyd Logo
Post-IPO Debt - Invivyd
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - Invivyd Logo
Post-IPO Debt - Invivyd
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - Invivyd Logo
Post-IPO Debt - Invivyd
—
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 22 Board Members and Advisors 5 Contacts 69

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 9, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

8,171
-32.37%
 in past month

IT Spend

$3.6MThis year, Invivyd is projected to spend $3.6M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Tom’s Guide Logo
Tom’s Guide
100
Configuration Options Logo
Configuration Options
96
Mobile Field Sales / Wireless Connectivity Logo
Mobile Field Sales / Wireless Connectivity
93

Active Website Tech Count

53Invivyd is actively using 53 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and  HSTS.

Total IP

32The intellectual property of Invivyd includes 7 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Invivyd has registered 25 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Invivyd's headquarters? Invivyd is located in Waltham, Massachusetts, United States.Who invested in Invivyd? Invivyd has 16 investors including Silicon Valley Bank and  OrbiMed.When was the last funding round for Invivyd? Invivyd closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Invivyd's competitors? Alternatives and possible competitors to Invivyd may include Wellgistics Health, XtalPi, and  Canton Strategic Holdings.How much funding has Invivyd raised to date? Invivyd has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(2e7868f 1)
|